Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
Drug Promotion - What We Know, What We Have Yet to Learn - Reviews of Materials in the WHO/HAI Database on Drug Promotion - EDM Research Series No. 032
(2004; 102 pages) View the PDF document
Table of Contents
View the documentAcknowledgements
View the documentExecutive summary
Open this folder and view contentsIntroduction
Open this folder and view contentsReview 1. What attitudes do professional and lay people have to promotion?
Open this folder and view contentsReview 2. What impact does pharmaceutical promotion have on attitudes and knowledge?
Open this folder and view contentsReview 3. What impact does pharmaceutical promotion have on behaviour?
Open this folder and view contentsReview 4. What interventions have been tried to counter promotional activities, and with what results?
View the documentFinal conclusions
View the documentReferences


Note: the availability of unpublished reference material (often a student thesis) is listed in the database entry (go to www.drugpromo.info, then the review article, and click on the entry number in the review article).

1 Peay, Marilyn Y. Peay, Edmund R. Differences among practitioners in patterns of preference for information sources in the adoption of new drugs. Social Science and Medicine 1984;18:1019-1025.

2. Gambrill, J. Bridges-Webb, C. Use of sources of therapeutic and prescribing information by general practitioners. Australian Family Physician 1980;9:482-484.

3. McCue, Jack D. Hansen, Charles J. Gal, Peter. Physicians’ opinions of the accuracy, accessibility, and frequency of use of ten sources of new drug information. Southern Medical Journal 1986;79:441-443.

4. Hodges, Brian. Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. Canadian Medical Association Journal 1995;153:553-559.

5. Sergeant, Myles D. Hodgetts, P. Geoffrey. Godwin, Marshall. Walker, David M. C. McHenry, Patty. Interactions with the pharmaceutical industry: a survey of family medicine residents in Ontario. Canadian Medical Association Journal 1996;155:1243-1248.

6. Aldir, Rodolfo E. Jarjoura, David. Phinney, Melinda. Poordad, Fred. Gutierrez, Robert. Marnejon, Thomas. Greifenstein, Elaine. Lappin, Joan. Whittier, Frederick C. Practicing and resident physician’s views on pharmaceutical companies. Journal of Continuing Education in the Health Professions 1996;16:25-32.

7. Barnes, Charles J. Holcenberg, John S. Student reactions to pharmaceutical promotion practices. Northwest Medicine 1971;70:262-266.

8. Blake, Robert L. Jr. Early, Elizabeth K. Patients’ attitudes about gifts to physicians from pharmaceutical companies. Journal of the American Board of Family Practice 1995;8:457-464.

9. Madhavan, S. Amonkar, M.M. Elliott, D. Burke, K. Gore, P. The gift relationship between pharmaceutical companies and physicians: an exploratory survey of physicians. Journal of Clinical Pharmacy and Therapeutics 1997;22:207-215.

10. Keim, Samuel M. Sanders, Arthur B. Witzke, Donald B. Dyne, Pamela. Fulgniti, John W. Beliefs and practices of emergency medicine faculty and residents regarding professional interactions with the biomedical industry. Annals of Emergency Medicine 1993;22:1576-1581.

11. Mainous, Arch G. III. Hueston, William J. Rich, Eugene C. Patient perceptions of physician acceptance of gifts from the pharmaceutical industry. Archives of Family Medicine 1995;4:335-339.

12. Reeder, Mike. Dougherty, James. White, Lynn J. Pharmaceutical representatives and emergency medicine residents: a national survey. Annals of Emergency Medicine 1993;22:1593-1596.

13. Strang, David. Gagnon, Micheline. Molloy, William. Bédard, Michel. Darzins, Peteris. Etchells, Edward. Davidson, Warren. National survey on the attitudes of Canadian physicians towards drug-detailing by pharmaceutical representatives. Annals of the Royal College of Physicians and Surgeons of Canada 1996;29:474-478.

14. Lichstein, Peter R. Turner, Robert C. O’Brien, Kevin. Impact of pharmaceutical company representatives on internal medicine residency programs: a survey of residency program directors. Archives of Internal Medicine 1992;152:1009-1013.

15. Dunn, Earl. William, J. Ivan. Bryans, A.M. Davis, David. Delmore, Terry. Herron, Anna. Krauser, John. Scott, David J. Continuing medical education in Ontario: a primary care perspective. Canadian Family Physician 1982;28:1327-1333.

16. McKinney, W. Paul. Schiedermayer, David L. Lurie, Nicole. Simpson, Deborah E. Goodman, Jesse L. Rich, Eugene C. Attitudes of internal medicine faculty and residents toward professional interactions with pharmaceutical sales representatives. JAMA 1990;264:1693-1697.

17. Bucci, Kathryn K. Frey, Keith A. Involvement of pharmacy faculty in the development of policies for pharmaceutical sales representatives. Journal of Family Practice 1992;34:49-52.

18. Hayes, T. M. Allery, L. A. Harding, K. G. Owen, P.A. Continuing education for general practice and the role of the pharmaceutical industry. British Journal of General Practice 1990;40:510-512.

19. Eaton, Gail. Parish, Peter. General practitioners’ views of information about drugs. Journal of the Royal College of General Practitioners 1976;26:64-68.

20. Thomson, A. N. Craig, B. J. Barham, P. M. Attitudes of general practitioners in New Zealand to pharmaceutical representatives. British Journal of General Practice 1994;44: 220-223.

21. McMillan, J. H. Information about medicines. New Zealand Medical Journal 1982;95:674-675.

22. Shearer, Stephen W. Gagnon, Jean Paul. Eckel, Fred M. Community, hospital and clinical pharmacists and drug information centers as physician drug information sources. American Journal of Hospital Pharmacy 1978;35:909-914.

23. Whelan, Ann Marie. Nagpal, Seema. Burge, Fred. Drug information resources in a family medicine residency training program. Canadian Pharmaceutical Journal 1994;127:39, 41-43, 46.

24. Cockerill, Rhonda. Williams, Paul. Report on the 1989 survey of the dispensing practices and attitudes toward prescription drugs of Ontario pharmacists. Toronto: Province of Ontario; 1990(?)

25. Boerkamp, E. J. C. Haaijer-Ruskmap, F. M. Reuyl, J. C. Versluis, A. The use of drug information sources by physicians: development of a data-generating methodology. Social Science and Medicine 1996;42:379-388.

26. Lion, John R. Regan, Bruce L. Taylor, Ronald J. Kutzer, Dennis J. Psychiatrists' opinions of psychotropic drug advertisements. Social Science & Medicine 1979;13A:123-125.

27. Güldal, Dilek. Semin, Semih. The influence of drug companies' advertising programs on physicians. International Journal of Health Services 2000;30:585-595.

28. Benseman, John. The great paper waste: the use of unsolicited medical literature by general practitioners. New Zealand Family Physician 1985;12:96-98.

29. Mackowiak, Elaine D. O'Connor, Thomas W. Geller, Hayley. Nguyen, Jessica. Wilkes, Wanda. A survey of pharmacists' and pharmacy students' attitudes toward OTC advertising. Journal of Pharmaceutical Marketing & Management 1997;12:33-49.

30. Africa survey shows pharma information valued. Health Horizons. October 1992:12-13.

31. van Trigt, Anke M. de Jong-van den Berg, Lolkje T. W. Haaijer-Ruskamp, Flora M. Willems Jaap. Tropm, Theo F.J. Journalists and their sources of ideas and informaton on medicines. Social Science and Medicine 1994;38:637-643.

32. Sigworth, Stephen K. Nettleman, Mary D. Cohen, Gail M. Pharmaceutical branding of resident physicians. JAMA 2001;286:1024-1025.

33. Palmisano, Paul. Edelstein, Joan. Teaching drug promotion abuses to health profession students. Journal of Medical Education 1980;55:453-455.

34. Gibbons, Robert V. Landry, Frank J. Blouch, Denise L. Jones, David L. Williams, Frederick K. Lucey, Catherine R. Kroenke, Kurt. A comparison of physicians’ and patients’ attitudes toward pharmaceutical industry gifts. Journal of General Internal Medicine 1998;13:151-154.

35. Bansinath, M. Sequeira, R. P. Shukla, V. K. Mathur, V. S. Brand versus generic prescribing: a perspective of the Indian cardiologists’ viewpoint. International Journal of Clinical Pharmacology, Therapy and Toxicology 1984;22:279-283.

36. Pitt, Leyland. Nel, Deon. Pharmaceutical promotion tools-their relative importance. European Journal of Marketing 1988;22:7-14.

37. Hume, Anne L. Shaughnessy, Allen F. Sources of influence on the prescribing practices of residents in family medicine. DICP, The Annals of Pharmacotherapy 1991;25:102-103.

38. Banks, James W. III. Mainous, Arch G. III. Attitudes of medical school faculty toward gifts from the pharmaceutical industry. Academic Medicine 1992;67:610-612.

39. Poirier, Therese I. Giannetti, Vincent. Giudici, Raymond A. Pharmacists’ and physicians’ attitudes toward phamaceutical marketing practices. American Journal of Hospital Pharmacy 1994;51:378-381.

40. La Puma, John. Stocking, Carol B. Rhoades, William D. Darling, Cheryl M. Financial ties as part of informed consent to post-marketing research: attitudes of American doctors and patients. BMJ 1995;310:1660-1663.

41. Prevention Magazine. International survey on wellness and consumer reaction to DTC advertising of prescription drugs. Vol.1. US report with international perspectives. Rodale Press, 2000/2001.

42. Petroshius, Susan M. Titus, Philip A. Hatch, Kathryn J. Physician attitudes toward pharmaceutical advertising. Journal of Advertising Research 1995;35:41-51.

43. Cutrer, Christine M. Pleil, Andreas M. Potential outcomes associated with direct-to-consumer advertising of prescription drugs: physicians’ perspectives. Journal of Pharmaceutical Marketing & Management 1991;5:3-19.

44. Lipsky, Martin S. Taylor, Christine A. The opinions and experiences of family physicians regarding direct-to-consumer advertising. Journal of Family Practice 1997;45:495-499.

45. Lipton, Charles. Consumer advertising and pharmaceuticals: a happy marriage? Journal of Pharmaceutical Marketing & Management 1986;1:23-28.

46. Bell, Robert A. Kravitz, Richard L. Wilkes, Michael S. Direct-to-consumer prescription drug advertising and the public. Journal of General Internal Medicine 1999;14:651-657.

47. Magazine Publishers of America. Magazines: a healthy diagnosis. Return on investment for DTC pharmaceutical advertising. A study measuring the effectiveness of allergy advertising by PERZ/HCI. New York: Magazine Publishers of America; 1999.

48. Maddox, Lynda M. Katsanis, Lea Prevel. Direct-to-consumer advertising of prescription drugs in Canada: its potential effect on patient-physician interaction. Journal of Pharmaceutical Marketing & Management 1997;12:1-21.

49. Rockwell, Tom. The Lifetime experience with prescription drug advertising exposed to consumers. Journal of Pharmaceutical Marketing & Management 1986;1:13-18.

50. Alperstein, Neil M. Peyrot, Mark. Consumer awareness of prescription drug advertising. Journal of Advertising Research 1993;33:50-56.

51. Mintzes, Barbara. Kazanjian. Bassett, Ken. Lexchin, Joel. An assessment of the health system impact of direct-to-consumer advertising of prescription medicines (DTCA). Volume IV: pills, persuasion and public health policies. Report of an expert survey on direct-to-consumer advertising of prescription drugs in Canada, the United States and New Zealand. Vancouver: Centre for Health Services & Policy Research; June 2001.

52. Control of drug advertising in Canada. Ottawa: Drugs Directorate; October 25, 1994.

53. Amonkar, Mayur Mohan. Lively, Buford T. Pharmacists' attitudes toward product-specific television advertising of prescription drugs. Journal of Pharmaceutical Marketing & Management 1996;11:3-20.

54. Linn, Lawrence S. Davis, Milton S. Physicians’ orientation toward the legitimacy of drug use and their preferred source of new drug information. Social Science and Medicine 1972;6:199-203.

55. Andaleeb, Syed Saad. Tallman, Robert F. Physician attitudes toward pharmaceutical sales representatives. Health Care Marketing Review 1995;20:68-76.

56. Stinson, E. Ray. Mueller, Dorothy A. Survey of health professionals’ information habits and needs: conducted through personal interviews. JAMA 1980;243:140-143.

57. Evans, Kenneth R. Beltramini, Richard F. Physician acquisition of prescription drug information. Journal of Health Care Marketing 1986;615-25.

58. Oppenheim, Gene L. Erickson, Steven H. Ashworth, Clark. The family physician’s knowledge of the cost of prescribed drugs. Journal of Family Practice 1981;12:1027-1030.

59. Miller, Lucinda G. Blum, Alan. Physician awareness of prescription drug costs: a missing element of drug advertising and promotion. Journal of Family Practice 1993;36:33-36.

60. Santell, John P. Sirdwell, Stephen W. Scheckelhoff, Douglas J. Perception of the role of medical-service representatives in hospitals. American Journal of Hospital Pharmacy 1990;47:1354-1359.

61. Hull, F. M. Marshall, T. Sources of information about new drugs and attitudes towards drug prescribing: an international study of differences between primary care physicians. Family Practice 1987;4:123-128.

62. Ziegler, Michael G. Lew, Pauline. Singer, Brian C. The accuracy of drug information from pharmaceutical sales representatives. JAMA 1995;273:1296-1298

63. Avorn, Jerry. Chen, Milton. Hartley, Robert. Scientific versus commercial sources of influence on the prescribing behavior of physicians. American Journal of Medicine 1982;73:4-8.

64. Greenwood, Justin. Pharmaceutical representatives and the prescribing of drugs by family doctors. Nottingham University; 1989 (unpublished).

65. Engle, Robert L. The impact of a single-advertiser publication on physicians’ perceptions and expected prescribing behavior. Journal of Pharmaceutical Marketing & Management 1994;8:37-54.

66. Sandberg, Warren S. Carlos, Ruth. Sandberg, Elisabeth H. Roizen, Michael F. The effect of educational gifts from pharmaceutical firms on medical students’ recall of company names or products. Academic Medicine 1997;72:16-918.

67. Spingarn, Roger W. Berlin, Jesse A. Strom, Brian L. When pharmaceutical manufacturers’ employees present grand rounds, what do residents remember? Academic Medicine 1996;71:86-88.

68. Sansgiry, Shubhada. Sharp, William T. Sansgiry, Sujit S. Consumer understanding and interpretation of printed over-the-counter drug advertisements. Journal of Pharmaceutical Marketing & Management 1999;13:15-26.

69. Ferry, Margaret E. Lamy, Peter P. Becker, Lorne A. Physicians’ knowledge of prescribing for the elderly: a study of primary care physicians in Pennsylvania. Journal of the American Geriatric Society 1985;33:616-622.

70. Moser, Robert H. The continuing search: FDA drug information survey. JAMA 1974;229:1336-1338.

71. Christensen, Dale B. Wertheimer, Albert I. Sources of information and influence on new drug prescribing among physicians in an HMO. Social Science and Medicine 1979;13A:313-322.

72. Ahmad, Syed Rizwanuddin. Bhutta, Zulfiqar Ahmed. A survey of pediatric prescribing and dispensing in Karachi. Journal of the Pakistan Medical Association 1990;40:126-130.

73. Tomson, G. Angunawela, I. Patients, doctors and their drugs: a study at four levels of health care in an area of Sri Lanka. European Journal of Clinical Pharmacology 1990;39:463-467.

74. Osiobe, Stephen A. Sources of information for biomedical decision-making. Methods of Information in Medicine 1985;24:225-229.

75. Osiobe, Stephen A. Physicians’ and pharmacists’ drug information sources in Nigeria. Drug Information Journal 1988;22:553-563.

76. Hatton, Randy C. Doering, Paul L. Frias, Jaime L. Physicians’ sources of information about teratogenic effects of drugs. Drug Information Journal 1982;16:148-154.

77. Williams, James R. Hensel, Paul J. Changes in physicians’ sources of pharmaceutical information: a review and analysis. Journal of Health Care Marketing 1991;11:46-60.

78. Abate, Marie A. Jacknowitz, Arthur I. Shumway, James M. Information sources utilized by private practice and university physicians. Drug Information Journal 1989;23:304-319.

79. Murray-Lyon, N. Communication in medicine: a study of how family doctors obtain information on recent advances in the treatment of rheumatic diseases. Medical Education 1997;11:95-102.

80. Gaither, Caroline A. Bagozzi, Richard P. Kirking, Duane M. Ascione, Frank J. Factors related to physicians’ attitudes and beliefs toward drug information sources. Drug Information Journal 1994;28:817-827.

81. Hibberd, Patricia L. Meadows, A. J. Use of drug information sources by hospital doctors. Journal of Information Science 1980;2:169-172.

82. Eaton, Gail. Parish, Peter. Sources of drug information used by general practitioners. Journal of the Royal College of General Practitioners 1976;26:58-64.

83. Strickland-Hodge, B. Jepson, M. H. Usage of information sources by general practitioners. Journal of the Royal Society of Medicine 1980;73:857-862.

84. Peay, Marilyn Y. Peay, Edmund R. Innovation in high risk drug therapy. Social Science and Medicine 1994;39:39-52.

85. Manning, Phil R. Denson, Teri A. How internists learned about cimetidine. Annals of Internal Medicine 1980;92:690-692.

86. Parboosingh, John. Lockyer, Jocelyn. McDougall, Gerald. Chugh, Urmil. How physicians make changes in their clinical practice: a study of physicians’ perception of factors that facilitate this process. Annals of the Royal College of Physicians and Surgeons of Canada 1984;17:429-435.

87. Williamson, P. M. How general practitioners assess risks in using new drugs. Journal of the Royal College of General Practitioners 1975;25:383-386.

88. Lefkowitz, David III. Rap sheet on reps: the doctor will see you now. Pharmaceutical Executive 1988;6:38-42

89. Jones, Miren I. Greenfield, Sheila M. Bradley, Colin P. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ 2001;323:378-384.

90. Greenwood, Justin. Prescribing and salesmanship. HAI News 989:1-2, 11.

91. Lexchin, Joel. Interactions between physicians and the pharmaceutical industry: what does the literature say? Canadian Medical Association Journal 1993;149:1401-1407.

92. Cardenas, Eduardo Zarate. Isenrich, Lucia Llosa. Prescribing habits of Peruvian physicians and factors influencing them. Bulletin of PAHO 1995;29:328-337.

93. Taylor, A. Violations of the international code of marketing of breast milk substitutes: prevalence in four countries. BMJ 1999;316:1117-1122.

94. Taylor, Ross J. Bond, Christine M. Change in the established prescribing habits of general practitioners: an analysis of initial prescriptions in general practice. British Journal of General Practice 1991;41:244-248.

95. Dasta, Joseph F. Visconti, James A. Hawksworth, K. The adoption of clarithromycin by university-based physicians during its first year of commercial availability. Journal of Pharmaceutical Marketing & Management 1995;9:3-20.

96. Peay, Marilyn Y. Peay, Edmund R. Patterns of preference for information sources in the adoption of new drugs by specialists. Social Science and Medicine 1990;31:467-476.

97. Curry, Lynn. Putnam, R. Wayne. Continuing medical education in Maritime Canada: the methods physicians use, would prefer and find most effective. Canadian Medical Association Journal 1981;124:563-566.

98. Lurie, Nicole. Rich, Eugene C. Simpson, Deborah E. Meyer, Jeff. Schiedermayer, David L. Goodman, Jesse L. McKinney, W. Paul. Pharmaceutical representatives in academic medical centers: interaction with faculty and housestaff. Journal of General Internal Medicine 1990;5:240-243.

99. Mapes, Roy. Aspects of British general practitioners’ prescribing. Medical Care 1977;15:371-381.

100. Bower, Anthony D. Burkett, Gary L. Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices. Journal of Family Practice 1987;24:612-616.

101. Caudill, T. Shawn. Johnson, Mitzi S. Rich, Eugene C. McKinney, W. Paul. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Archives of Family Medicine 1996;5:201-206.

102. Becker, Marshall H. Stolley, Paul D. Lasagna, Louis. McEvilla, Joseph D. Sloane, Lois M. Differential education concerning therapeutics and resultant physician prescribing patterns. Journal of Medical Education 1972;47:118-127.

103. Stolley, Paul D. Becker, Marshall H. Lasagna, Louis. McEvilla, Joseph D. Sloane, Lois M. The relationship between physicians characteristics and prescribing appropriateness. Medical Care 1972;10:17-28.

104. Haayer, Flora. Rational prescribing and sources of information. Social Science and Medicine 1982;16:2017-2023.

105. Cormack, M. A. Howells, E. Factors linked to the prescribing of benzodiazepines by general practice principals and trainees. Family Practice 1992;9:466-471.

106. Williams, A. Paul. Cockerill, Rhonda. Report on the 1989 survey of the prescribing experiences and attitudes toward prescription drugs of Ontario physicians. Toronto: Government of Ontario; 1990(?).

107. Stross, Jeoffrey K. Information sources and clinical decisions. Journal of General Internal Medicine 1987;2:155-159.

108. Strickland-Hodge, B. Jepson, M. H. Identification and characterization of early and late prescribers in general practice. Journal of the Royal Society of Medicine 1982;75:341-345.

109. Peay, Marilyn Y. Peay, Edmund R. The role of commercial sources in the adoption of a new drug. Social Science and Medicine 1988;26:1183-1189.

110. Orlowski, James P. Wateska, Leon. The effects of pharmaceutical firm enticements on physician prescribing patterns: there’s no such thing as a free lunch. Chest 1992;102:270-273.

111. Gönül, Füsun. F. Carter, Franklin. Petrova, Elina. Srinivasan, Kannan. Promotion of prescription drugs and its impact on physicians' choice behavior. Journal of Marketing 2001;65:79-90.

112. Walton, Harold. Ad recognition and prescribing by physicians. Journal of Advertising Research 1980;20:39-48.

113. Walton, Harold. A case for medical journal advertising. Medical Marketing & Media 1978;13:37-43.

114. AD/Rx: 1993 annual analysis. Kulpsville, Pennsylvania: Consultants in Pharmaceutical Media, Inc; 1993.

115. American Business Press, Advertising Research Foundation. Product growth: how can it be achieved in an era of tighter resources? New York: American Business Press; 1993.

116. Leisten, Volker. Schmieder, Wilfried. Wenzel, Jnrgen. Proof of effectiveness: “pharmaads”. Arbeitsgemeinschaft LAMED; October 1993.

117. Hemminki, Elina. The effect of a doctor’s personal characteristics and working circumstances on the prescribing of psychotropic drugs. Medical Care 1974;12:351-357.

118. Berings, D. Blondeel, L. Habraken, H. The effect of industry-independent drug information on the prescribing of benzodiazepines in general practice. European Journal of Clinical Pharmacology 1994;46:501-505.

119. Williams, Paul A. Cockerill, Rhonda. Lowy, Frederick H. The physician as prescriber: relations between knowledge about prescription drugs, encounters with patients and the pharmaceutical industry, and prescription volume. Health and Canadian Society 1995;3;135-166.

120. Matalia, Ned. Journal advertising works! Three studies say so! Medical Marketing & Media 1994;29:12-14, 16, 18-20.

121. Backer, Elisabeth L. Lebsack, Jason A. van Tonder, R.J.N. Crabtree, Benjamin F. The value of pharmaceutical representative visits and medication samples in community-based family practices. Journal of Family Practice 2000;49:811-816.

122. Morelli, Daniel. Koenigsberg, Marlon Russell. Sample medication dispensing in a residency practice. Journal of Family Practice 1992;34:42-48.

123. Chew, Lisa D. O'Young, Theresa S. Hazlet, Thomas K. Bradley, Katharine A. Maynard, Charles. Lessler, Daniel S. A physician survey of the effect of drug sample availability on physicians' behavior. Journal of General Internal Medicine 2000;15:478-483.

124. Westfall, John M. McCabe, Jennifer. Nicholas, Richard A. Personal use of drug samples by physicians and office staff. JAMA 1997;278:141-143.

125. Tong, Kevin L. Lien, Chia-Yen. Do pharmaceutical representative misuse their drug samples? Canadian Family Physician 1995;41:1363-1366.

126. Cleary, John D. Impact of pharmaceutical sales representatives on physician antibiotic prescribing. Journal of Pharmacy Technology 1992;8:27-29.

127. Dieperink, Michael. Drogemuller, Lisa. Industry-sponsored grand rounds and prescribing behavior. JAMA 2001;285:1443-1444.

128. Stern, Robert S. Drug promotion for an unlabeled indication; the case of topical tretinoin. New England Journal of Medicine 1994;331:1348-1349.

129. Eichner, Riva. Maronick, Thomas J. A review of direct-to-consumer (DTC) advertising and sales of prescription drugs: does DTC advertising increase sales and market share? Journal of Pharmaceutical Marketing & Management 2001;13:19-42.

130. Mackowiak, John I. Gagnon, Jean Paul. Effects of promotion on pharmaceutical demand. Social Science and Medicine 1985;20:1191-1197.

131. Basara, Lisa Ruby. The impact of a direct-to-consumer prescription medication advertising campaign on new prescription volume. Drug Information Journal 1996;30:715-729.

132. Zachry, Woodie M. III. Shepherd, Marvin D. Hinich, Melvin J. Wilson, James P. Brown, Carolyn M. Lawson, Kenneth A. Relationship between direct-to-consumer advertising and physician diagnosing and prescribing. American Journal of Health-System Pharmacy 2002;59:42-49.

133. Krupka, Lawrence R. Vener, Arthur M. Prescription drug advertising: trends and implications. Social Science and Medicine 1985;20:191-197.

134. Dajda, Richard. Drug advertising and prescribing. Journal of the Royal College of General Practitioners 1978;28:538-541.

135. Suresh, C. G. Greene D. Coupe, M. O. Use of adenosine and effectiveness of pharmaceutical marketing. Lancet 1993;341:1539.

136. Chren, Mary-Margaret. Landefeld, C. Seth. Physicians’ behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994;271:684-689.

137. Mintzes, Barbara. An assessment of the health system impact of direct-to-consumer advertising of prescription medicines (DTCA). Volume II: literature review. Direct-to-consumer advertising of prescription drugs: what do we know thus far about its effects on health and health care services? Vancouver: Centre for Health Services and Policy Research; August 2001.

138. Everett, Stephen E. Lay audience response to prescription drug advertising. Journal of Advertising Research 1991;31:43-49.

139. Bell, Robert A. Wilkes, Michael S. Kravitz, Richard L. Advertisement-induced prescription drug requests: patients' anticipated reactions to a physician who refuses. Journal of Family Practice 1999;48:446-452.

140. Perri, Matthew. Dickson, W. Michael. Direct to consumer prescription drug advertising: consumer attitudes and physician reaction. Journal of Pharmaceutical Marketing & Management 1987;2:3-25.

141. Morris, Louis A. Mazis, Michael B. Brinberg, David. Risk disclosures in televised prescription drug advertising to consumers. Journal of Public Policy & Marketing 1989;8:64-80.

142. Morris, Louis A. Millstein, Lloyd G. Drug advertising to consumers: effects of formats for magazine and television advertisements. Food Drug Cosmetic Law Journal 1984;39:497-503.

143. Mintzes, Barbara. Barer, Morris L. Kravitz, Richard L. Kazanjian, Armin Te. Bassett, Ken. Lexchin, Joel. Evans, Robert G. Pan, Richard. Marion, Stephen A. Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ 2002;324:278-279.

144. Bowman, Marjorie A. The impact of drug company funding on the content of continuing medical education. Mobius 1986;6:66-69.

145. Bowman, Marjorie A. Pearle, David L. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. Journal of Continuing Education 1988;8:13-20.

146. Massie, B. M. Rothenberg, D. Impact of pharmaceutical industry funding of clinical research: results of a survey of antianginal trials. Circulation 1984;70:II-390.

147. Anderson, Jennifer J. Felson, David T. Meenan, Robert F. Secular changes in published clinical trials of second-line agents in rheumatoid arthritis. Arthritis and Rheumatism 1991;34:1304-1309.

148. Kunin, Calvin M. Clinical investigators and the pharmaceutical industry. Annals of Internal Medicine 1978;89:842-845.

149. Dorman, Paul J. Counsell, Carl. Sandercock, Peter. Reports of randomized trials in acute stroke, 1955 to 1995: what proportions were commercially sponsored? Stroke 1999;30:1995-1998.

150. Blumenthal, David. Gluck, Michael. Louis, Karen Seashore. Stoto, Michael A. Wise, David. University-industry research relationships in biotechnology: implications for the university. Science 1986;232:1361-1366.

151. Krimsky, Sheldon. Ennis, James G. Weissman, Robert. Academic-corporate ties in biotechnology: a quantitative study. Science, Technology, & Human Values 1991;16:275-287.

152. Blumenthal, David. Causino, Nancyanne. Campbell, Eric. Louis, Karen Seashore. Relationships between academic institutions and industry in the life sciences: an industry survey. New England Journal of Medicine 1996;334:368-373.

153. Blumenthal, David. Campbell, Eric G. Anderson, Melissa S. Causino, Nancyanne. Louis, Karen Seashore. Withholding research results in academic life science: evidence from a national survey of faculty. JAMA 1997;277:1224-1228.

154. Blumenthal, David. Campbell, Eric G. Causino, Nancyanne Louis, Karen Seashore. Participation of life science faculty in research relationships with industry. New England Journal of Medicine 1996;335:1734-1739.

155. Campbell, Eric G. Louis, Karen Seashore. Blumenthal, David. Looking a gift horse in the mouth: corporate gifts supporting life sciences research. JAMA 1998;279:995-999.

156. Choudhry, Niteesh K. Stelfox, Henry Thomas. Detsky, Allan S. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002;287:612-617.

157. Easterbrook, Philippa J. Berlin, Jesse A. Gopalan, Ramana. Matthews, David R. Publication bias in clinical research. Lancet 1991;337:867-872.

158. Stern, Jerome M. Simes, R. John. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997;315:640-645.

159. Ioannidis, John P.A. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998;279:281-286.

160. Dickersin, Kay. Min, Yuan-I. Meinert, Curtis L. Factors influencing publication of research results: follow-up of applications submitted to two institutional review boards. JAMA 1992;267:374-378.

161. Huston, Patricia. Moher, David. Redundancy, disaggregation, and the integrity of medical research. Lancet 1996;347:1024-1026.

162. Johansen, Helle Krogh. Gotzsche, Peter C. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999;282:1752-1759.

163. Stelfox, Henry Thomas. Chua, Grace. O’Rourke, Keith. Detsky, Allan S. Conflict of interest in the debate over calcium-channel antagonists. New England Journal of Medicine 1998;338:101-106.

164. Kemmeren, Jeanet M. Algra, Ale. Grobbee, Diederick E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323:131-134.

165. Vandenbroucke, Jan P. Helmerhorst, Frans M. Rosendaal, Frits R. Competing interests and controversy about third generation oral contraceptives. BMJ 2000;320:381-382.

166. Mandelkern, Marshal. Manufacturer support and outcome. Journal of Clinical Psychiatry 1999;60:122.

167. Wahlbeck, Kristian. Adams, Clive. Sponsored drug trials show more-favourable outcomes. BMJ 1999;318:465.

168. Cho, Mildred K. Bero, Lisa A. The quality of drug studies published in symposium proceedings. Annals of Internal Medicine 1996;124:485-489.

169. Rochon, Paula A. Gurwitz, Jerry H. Simms, Robert W. Fortin, Paul R. Felson, David T. Minaker, Kenneth L. Chalmers, Thomas C. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Archives of Internal Medicine 1994;154:157-163.

170. Liebeskind, David S. Kidwell, Chelsea S. Saver, Jeffrey L. Empiric evidence of publication bias affecting acute stroke clinical trials. Stroke 1999;30:268.

171. Azimi, Nassir A. Welch, H. Gilbert. The effectiveness of cost-effectiveness analysis in containing costs. Journal of General Internal Medicine 1998;13:664-669.

172. Friedberg, Mark. Saffran, Bernard. Stinson, Tammy J. Nelson, Wendy. Bennett, Charles L. Evaluation of conflict of interest in economic drugs used in oncology. JAMA 1999;282:1453-1457.

173. Davidson, Richard A. Source of funding and outcome of clinical trials. Journal of General Internal Medicine 1986;1:155-158.

174. Jadad, Alejandro R. Moher, Michael. Browman, George P. Booker, Lynda Sigouin, Christopher. Fuentes, Mario. Stevens, Robert. Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. BMJ 2000;320:537-540.

175. Djulbegovic, Benjamin. Lacevic, Mensura. Cantor, Alan. Fields, Karen K. Bennett, Charles L. Adams, Jared R. Kuderer, Nicole M. Lyman, Gary H. The uncertainty principle and industry-sponsored research. Lancet 2000;356:635-638.

176. Djulbegovic, B. Bennett, C.L. Lyman, G.H. Violation of the uncertainty principle in conduct of randomized controlled trials (RCTs) of erythropoietin (EPO). Blood 1999;94:399a

177. Tallon, Deborah. Chard, Jiri. Dieppe, Paul. Relation between agendas of the research community and the research consumer. Lancet 2000;355:2037-2040.

178. Tramer, Martin R. Reynolds, D. John M. Moore, R. Andrew. McQuay, Henry J. Impact of covert duplicate publication on meta-analysis: a case study. BMJ 1997;315:635-640.

179. Knox, K.S. Adams, J.R. Djulbegovic, B. Stinson, T.J. Tomori, C. Bennett, C.L. Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. Annals of Oncology 2000;11:1591-1595.

180. Kjaergard, Lise Lotte. Nikolova, Dimitrinka. Gluud, Christian. Randomized clinical trials in Hepatology: predictors of quality. Hepatology 1999;30:1134-1138.

181. Freemantle, N. Anderson, I.M. Young, P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs: meta-regression analysis. British Journal of Psychiatry 2000;177:292-302.

182. Dieppe, Paul. Chard, Jiri. Tallon, Deborah. Egger, Matthias. Funding clinical research. Lancet 1999;353:1626.

183. Chard, Jiri A. Tallon, Deborah. Dieppe, Paul A. Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint. Annals of the Rheumatic Diseases 2000;59:414-418.

184. Wilkes, Michael S. Kravitz, Richard L. Policies, practices, and attitudes of North American medical journal editors. Journal of General Internal Medicine 1995;10:443-450.

185. Sacristan, José A. Bolaños, Elena, Hernández, Jess. Soto, Javier. Galende,. Publication bias in health economic studies. Pharmacoeconomics 1997;11:289-291.

186. Moynihan, Ray. Bero, Lisa. Ross-Degnan, Dennis. Henry, David. Lee, Kirby. Watkins, Judy. Mah, Connie. Soumerai, Stephen B. Coverage by the news media of the benefits and risks of medications. New England Journal of Medicine 2000;342:1645-1650.

187. Lexchin, Joel. Enforcement of codes governing pharmaceutical promotion: what happens when companies breach advertising guidelines? Canadian Medical Association Journal 1997;156:351-356.

188. Herxheimer, Andrew. Collier, Joe. Promotion by the British pharmaceutical industry, 1983-8: a critical analysis of self regulation. BMJ 1990;300:307-311.

189. Morgan, A. H. Jeffers, T. A. Petrie, J. C. Walker W. Drug advertising in medical journals. British Journal of Clinical Pharmacology 1976;3:1057-1060.

190. Chirac, P. Pikon, A. Poinsignon, Y. Vitry, A. Drug marketing in French-speaking African countries. Social Science and Medicine 1993;36:1541-1543.

191. Dikshit, R. K. Dikshit, N. Commercial source of drug information: comparison between the United Kingdom and India. BMJ 1994;309:990-991.

192. Vo-Kyung, Song. Ok Kim, Jai. Investigation of the violations of pharmaceutical regulations in advertisements of children’s medicines. Manila:1988.

193. Lal, A. Moharana, A. K. Chandra, P. Ray, A. Critical evaluation of references in drug advertisements: an Indian experience. Journal of the Association of Physicians of India 1996;44:778-779.

194. Tomson, Göran. Weerasuriya, Kris. ‘Codes’ and practice: information in drug advertisement sùan example from Sri Lanka. Social Science and Medicine 1990;31:737-741.

195. Roth, Martin S. Patterns in direct-to-consumer prescription drug print advertising and their public policy implications. Journal of Public Policy & Marketing 1996;15:63-75.

196. Rothermich, Elizabeth A. Pathak, Dev S. Smeenk, David A. Health-related quality-of-life claims in prescription drug advertisements. American Journal of Health-Systems Pharmacy 1996;53:1565-1569.

197. Office of Inspector General. Prescription drug advertisements in medical journals. Washington, DC: Department of Health and Human Services; 1992(?).

198. Wilkes, Michael S. Doblin, Bruce H. Shapiro, Martin F. Pharmaceutical advertisements in leading medical journals: experts’ assessments. Annals of Internal Medicine 1992;116:912-919.

199. Lexchin, Joel. Holbrook, Anne. Methodologic quality and relevance of references in pharmaceutical advertisements in a Canadian medical journal. Canadian Medical Association Journal 1994;151:47-54.

200. Moulds, R. F. W. Bochner, F. Wing, I. M. H. Drug advertising. Medical Journal of Australia 1986;145:178-179.

201. Carandang, Edelisa D. Moulds, Robert F. W. Pharmaceutical advertisements in Australian medical publications - have they improved?. Medical Journal of Australia 1994;161:671-672.

202. Lexchin, Joel. Drug promotion. New Zealand Medical Journal 1987;100:754.

203. Peacock, Susan. Two surveys of pharmaceutical promotion and advertising. Wellington, NZ: Public Health Association of New Zealand; September 1990.

204. Sencan, Nazli. Üstell, Ismail. Information in drug advertisements. 1992 (unpublished)

205. Najman, Jackob M. Siskind, Victor. Bain, Christopher. Prescription drug advertising: medical journal practices under different types of control. Medical Journal of Australia 1979;1:420-424.

206. Fisherow, W. Benjamin. The shape of prescription drug advertising: a survey of promotional techniques and regulatory trends. Food Drug Cosmetic Law Journal 1987;42:213-236.

207. Wilkes, Michael S. Bell, Robert A. Kravitz, Richard L. Direct-to-consumer prescription drug advertising: trends, impact, and implications. Health Affairs 2000;19:110-128.

208. Morris, Louis A. Brinberg, David. Klimberg, Ronald. Millstein, Lloyd. Rivera, Carole. Consumer attitudes about advertisements for medicinal drugs. Social Science & Medicine 1986;22:629-636.

209. Larson, Lon N. Smith, Mickey C. Sharpe, Thomas R. Hy, Ronn. Garner, Dewey D. Government regulation and the believability of prescription drug advertising: an application of attribution theory and test of symbolic impact. Drug Intelligence and Clinical Pharmacy 1977;11:338-343.

210. Larson, Lon N. Smith, Mickey C. An analysis of the effects of fair balance” in prescription drug advertising. Medical Marketing & Media 1978;13:26-27, 31.

211. Hurd, Peter. The potential value of unfavorable information. Medical Marketing & Media 1980;15:42-44, 46.

212. Cady, Paul S. Larson, Lon N. Brief summary and the believability of consumer prescription drug advertising. Journal of Pharmaceutical Marketing & Management 1989;3:65-72.

213. Schommer, Jon C. Doucette, William R. Mehta, Bella H. Rote learning after exposure to a direct-to-consumer television advertisement for a prescription drug. Clinical Therapeutics 1998;20:617-632.

214. Tucker, Gregory K. Smith, Mickey C. Direct-to-consumer advertising: effects of different formats of warning information disclosure on cognitive reactions of adults. Journal of Pharmaceutical Marketing & Management 1987;2:27-41.

215. Roughead, Elizabeth E. Gilbert, Andrew L. Harvey, Ken J. Self-regulatory codes of conduct: are they effective in controlling pharmaceutical representatives’ presentations to general medical practitioners? International Journal of Health Services 1998;28:269-279.

216. Roughead, Elizabeth Ellen. The pharmaceutical representative and medical practitioner encounter: implications for quality use of medicines. Bundoora, Australia: La Trobe University; August 1995.

217. Bardelay, Danielle. Bécel, Bernard. Visits from medical representatives: fine principles, poor practice. Prescrire International 1995;4:120-122.

218. Sales representatives: a damning report by Prescrire reps monitoring network. Prescrire International 1999;8:86-89.

219. Waller, P. C. Wood, S. M. Langman, M. J. S. Breckenridge, A. M. Rawlins, M. D. Review of company post-marketing surveillance studies. BMJ 1992;304:1470-1472.

220. Bero, Lisa A. Rennie, Drummond. Influences on the quality of published drug studies. International Journal of Technology Assessment in Health Care 1996;12:209-237.

222. Inman, William. Pearce, Gillian. Prescriber profile and post-marketing surveillance. Lancet 1993;342:658-661.

223. Lo, Bernard. Wolf, Leslie E. Berkeley, Abiona. Conflict-of-interest policies for investigators in clinical trials. New England Journal of Medicine 2000;343:1616-1620.

224. van McCrary, S. Anderson, Cheryl B. Jakovljevic, Jelena. Khan, Tonya. McCullough, Laurence B. Wray, Nelda P. Brody, Baruch A. A national survey of policies on disclosure of conflicts of interest in biomedical research. New England Journal of Medicine 2000;343:1621-1626.

225. Alloza, José Luis. Lasagna, Louis. A comparison of drug product information in four national compendia. Clinical Pharmacology and Therapeutics 1983;33:269-277.

226. Osifo, Nosakhare Guy. Overpromotion of drugs in international product package inserts. Tropical Doctor 1983;13:5-8.

227. US Congress, Office of Technology Assessment. Drug labeling in developing countries. Washington, DC: US Government Printing Office; February 1993.

228. Mahood, S. Zagozeski, C. Bradel, T. Lawrence, K. Pharmaceutical policies in Canadian family medicine training: survey of residency programs. Canadian Family Physician 1997;43:1947-1951.

229. Brotzman, Gregory L. Mark, David H. Policies regulating the activities of pharmaceutical representatives in residency programs. Journal of Family Practice 1992;34:54-57.

230. Thomas, Joseph III. National survey of hospital policies on pharmaceutical sales representatives' activities. American Journal of Hospital Pharmacy 1987;44:1334-1340

231. Thomas, Joseph III. National survey of recent changes in hospital policies on pharmaceutical sales representatives’ activities. American Journal of Hospital Pharmacy 1989;46:565-569.

232. Jewesson, Peter. Herar, Suman. Activities of pharmaceutical industry representatives at a major teaching hospital. Canadian Journal of Hospital Pharmacy 1996;49:256-260.

233. Brotzman, Gregory L. Mark, David H. The effect on resident attitudes of regulatory policies regarding pharmaceutical representative activities. Journal of General Internal Medicine 1993;8:130-134.

234. Ferguson, Robert P. Rhim, Eugene. Belizaire, Waindel. Egede, Leonard. Carter, Kennita. Lansdale, Thomas. Encounters with pharmaceutical sales representatives among practicing internists. American Journal of Medicine 1999;107:149-152.

235. McCormick, Brendan B. Tomlinson, George. Brill-Edwards, Patrick. Detsky, Allan S. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. JAMA 2001;286:1994-1999.

236. Anastasio, Geraldine D. Little, John M. Pharmaceutical marketing: implications for medical residency training. Pharmacotherapy 1996;16:103-107.

237. Kelcher, Sheila. Brownoff, Rene. Meadows, Lynn M. Structured approach to pharmaceutical representatives: family medicine residency program. Canadian Family Physician 1998;44:1053-1060.

238. Hopper, John A. Speece, Mark W. Musial, Joseph L. Effects of an educational intervention on residents’ knowledge and attitudes toward interactions with pharmaceutical representatives. Journal of General Internal Medicine 1997;12:639-642.

239. Suryawati, Sri. Santoso, Budiono. Drug advertisements: a critical lesson for Indonesian students. Essential Drugs Monitor 1997;23.

240. Shaughnessy, Allen F. Slawson, David C. Bennett, Joshua H. Teaching information mastery: evaluating information provided by pharmaceutical representatives. Family Medicine 1995;27:581-585.

241. Vinson, Daniel C. McCandless, Bridget. Hosokawa, Michael C. Medical students’ attitudes toward pharmaceutical marketing: possibilities for change. Family Medicine 1993;25:31-33.

242. Wilkes, Michael S. Hoffman, Jerome R. An innovative approach to educating medical students about pharmaceutical promotion. Academic Medicine 2001;76:1271-1277.

243. This month.- the results of MaLAM’s questionnaire to our subscribers. MaLAM Australian News 1996;4:1-5.

244. ACE inhibitors. Healthy Scepticism 1998;1:3-4.

245. Advertising of antibacterials. Healthy Skepticism 1999;2:1-5.

246. Advertising of CCBs for hypertension. Healthy Skepticism 1999;2:3-4.

247. Wade, V. A. Mansfield, P. R. McDonald, P. J. Drug companies’ evidence to justify advertising. Lancet 1989;2:1261-1264.

248. Mansfield, Peter R. Classifying improvements to drug marketing and justifications for claims of efficacy. International Journal of Risk & Safety in Medicine 1991;2:171-184.

249. Hoechst to discontinue Baralgin (dipyrone/pitofenone/fenpiverinium). MaLAM International News 1995;13:2.

250. Silverman, Milton. The epidemiology of drug promotion. International Journal of Health Services 1977;7:157-166.

251. Silverman, Milton. Lee, Philip R. Lydecker, Mia. Prescriptions for death: the drugging of the Third World. Berkeley: University of California Press;1982.

252. Silverman, Milton. Lee, Philip R. Lydecker, Mia. The drugging of the Third World. International Journal of Health Services 1982;12:585-596.

253. Silverman, Milton. Lee, Philip R. Lydecker, Mia. Drug promotion: the Third World revisited. International Journal of Health Services 1986;16:659-667.

254. Silverman, Milton. Lydecker, Mia. Lee, Philip R. Bad medicine: the prescription drug industry in the Third World. Stanford: Stanford University Press;1992.

to previous section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: June 25, 2014